Repertoire Immune Medicines Announces Cellular Publication Characterizing T Cell Response to New Highly Immunogenic SARS-CoV-2 Epitopes

Study Provides Insight into Raised Cellular Immunity to SARS-CoV-2 Peptides Generated from Non-canonical Genome Translations

New epitopes discovered by Sabeti Lab, Broad Institute of MIT and Harvard; Response of T lymphocyte memory in individuals identified and elucidated by Repertoire’s DECODE ™ platform

Repertoire Immune Medicines, a clinical-stage biotechnology company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious diseases and other serious illnesses, today announced the release of a new research that provides new information on how SARS-CoV-2 infected cells interact with the immune system. These results, published online in the peer-reviewed journal Cell, provide a new understanding of viral antigen presentation – from canonical open reading frames (ORFs) and out of frame internal ORFs – and how they may aid in the selection of peptide epitopes for immune surveillance and the development of vaccines against SARS-CoV-2 and other disease areas.

This press release features multimedia. View the full release here:

Daniel Pregibon, Ph.D., Discovery and Technology Platform Manager, Immune Drug Directory (Photo: Business Wire)

The manuscript, SARS-CoV-2 HLA-I peptidome profiling reveals T cell epitopes from out-of-frame ORFs, highlights the results of the first examination of SARS-CoV-2 antigen presentation in infected human cell lines using a method called immunopeptidomics. The approach revealed the presentation of several unexpected peptides derived from non-canonical reading frames of the SARS-CoV-2 genome, which were subsequently shown to be relevant in disease using a transgenic mouse model and of human COVID patients. Together, these tests revealed high T cell responsiveness to novel peptides, a peptide that generates greater responses in COVID-19 patients than some of the more immunodominant T cell epitopes described in previous scientific literature.

The study was conducted by researchers at Sabeti Lab, Broad Institute at MIT, and Harvard, and led by Pardis Sabeti, MD, D.Phil. The biological importance of these findings in infected individuals was demonstrated using Repertoire’s proprietary DECODE ™ platform. Thanks to DECODE, researchers discovered the T cells that recognize epitopes in recovering patients.

“We were delighted to collaborate on this exciting project, which exposes a surprising and uncharacterized source of T cell epitopes from the SARS-CoV-2 genome,” said Shira Weingarten-Gabbay, Ph.D., Broad Institute . “The information from this work increases our understanding of the interaction between SARS-CoV-2 and the immune system, and could potentially spread to other pathogens.”

“The results of this research provide important information on the nature and dynamics of viral protein expression and presentation in COVID-19,” said Daniel Pregibon, Ph.D., head of discovery and development. platform technology, Directory. “We are delighted to have been able to use Repertory technology to demonstrate the relevance of the novel epitopes discovered by Sabeti Lab’s immunopeptidomics approach, and we look forward to advancing science in this area to better design next-generation vaccines. for COVID-19 and beyond. “

About the Immune Drug Directory

Repertoire Immune Medicines is a fully integrated immune drug company dedicated to creating treatments for serious illnesses based on the power of the human T cell repertoire to kill cancer cells, target pathogens and regulate immune function. Repertoire’s strategy lies in understanding the immune synapse – the interaction between specific T cells and the corresponding antigen presenting cells that dictate T cell activity. The company’s proprietary DECODE ™ technology platform, developed by Repertoire scientists, provides a unique understanding of the complete repertoire of interactions between T cell receptors (TCRs) and their antigenic targets. The ability to decode these interactions represents one of the greatest opportunities for innovation in medical science.

Directory’s team of more than 120 people operates from sites in Cambridge, Massachusetts and Zurich, Switzerland, using its DECODE technology to rationally design treatments for cancers, autoimmune diseases and infectious diseases. The company’s first clinical product, for metastatic solid tumors, is a novel multiclonal T cell therapy composed of rare and naive T cells derived from peripheral blood, activated against a set of selected antigens and armed with a payload of proprietary cytokines. In the area of ​​autoimmunity, Repertoire has discovered new immune targets in patients with type 1 diabetes and other autoimmune diseases, providing the basis for new therapeutic candidates. The company is also using its DECODE platform to discover infectious disease antigens and responding T cell clones, providing the opportunity to develop targeted drugs for infectious diseases. To date, the company has raised more than $ 350 million from leading healthcare investors.

To learn more about Repertoire Immune Medicines, please visit our website: and follow us on LinkedIn and Twitter.

See the source version on


Investor contact:
Kendall Investor Relations
Andrew Funderburk
[email protected]

Media contact:
Scientific public relations
Lindsay G. Deefholts
[email protected]

Source link

Comments are closed.